

Contents

List of Contributors xv

- 1 **Current Understanding of Alzheimer's Disease and Other Neurodegenerative Diseases, and the Potential Role of Diet and Lifestyle in Reducing the Risks of Alzheimer's Disease and Cognitive Decline** 1
Charles S. Brennan, Margaret A. Brennan, W.M.A.D. Binosha Fernando and Ralph N. Martins
 References 7
- 2 **Alzheimer's Disease and Other Neurodegenerative Diseases** 9
Stephanie J. Fuller, Hamid R. Sohrabi, Kathryn G. Goozee, Anoop Sankaranarayanan and Ralph N. Martins
 - 2.1 Introduction 9
 - 2.2 Alzheimer's Disease 9
 - 2.2.1 Pathology 9
 - 2.2.2 Symptoms 10
 - 2.2.3 Incidence 11
 - 2.2.4 Onset and Risk Factors 12
 - 2.2.5 Treatment 12
 - 2.2.6 Potential for AD Prevention 13
 - 2.3 Frontotemporal Lobe Dementia 13
 - 2.3.1 Neuropathology and Causes 14
 - 2.3.2 Treatment 15
 - 2.3.3 Diagnosis and Clinical Overlap with Other Diseases 15
 - 2.4 Vascular Dementia 16
 - 2.4.1 Symptoms and Diagnosis 16
 - 2.4.2 Causes and Risk Factors 16
 - 2.4.3 Prevention and Treatment 17
 - 2.4.4 Dementia with Lewy Bodies 18
 - 2.4.5 Causes 18
 - 2.4.6 Symptoms 18
 - 2.4.7 Diagnosis of DLB 18
 - 2.4.7.1 Clinical Approach to Dementias 19

2.5	Parkinson's Disease	19
2.5.1	Onset	22
2.5.2	Causes and Risk Factors	22
2.5.3	Incidence	22
2.5.4	Pathology	22
2.5.5	Treatment	23
2.6	Huntington's Disease	24
2.6.1	Genetics of the Disease	24
2.6.2	Incidence and Prevalence	25
2.6.3	Pathology	25
2.6.4	Treatment	26
2.7	Motor Neuron Diseases	27
2.7.1	Amyotrophic Lateral Sclerosis	27
2.7.2	Spinal Muscular Atrophy	27
2.7.3	Hereditary Spastic Paraplegia	27
2.7.4	Onset of MND and Differential Diagnosis	28
2.7.5	Incidence, Causes, and Risk Factors	28
2.7.6	Pathology	29
2.7.7	Treatment	30
2.8	Prion Diseases	30
2.8.1	Causes	31
2.8.2	Symptoms and Diagnosis	31
2.8.3	Treatment	32
2.8.4	Differential Diagnosis of the Various Types of Dementia	32
2.8.5	DLB Treatment	33
2.9	Summary	33
	References	34

3 Current and Developing Methods for Diagnosing Alzheimer's Disease 43

Stephanie J. Fuller, Nicholas Carrigan, Hamid R. Sohrabi and Ralph N. Martins

3.1	Introduction	43
3.2	Classical Post-Mortem Diagnosis	43
3.2.1	Plaques	44
3.2.2	Neurofibrillary Tangles (NFT)	44
3.2.3	Cerebral Amyloid Angiopathy (CAA)	44
3.2.4	Glial Responses	45
3.2.5	Brain Shrinkage	45
3.2.6	Loss of Synapses and Neurons	45
3.3	Clinical Diagnosis	45
3.3.1	Initial Assessment/Screening Tools	47
3.3.1.1	Mini-Mental State Examination (MMSE)	47
3.3.1.2	Montreal Cognitive Assessment (MoCA)	47
3.3.1.3	Clinical Dementia Rating (CDR)	47
3.3.1.4	Clock Drawing	48
3.3.1.5	Seven-Minute Screen	48
3.3.1.6	Alzheimer's Disease Assessment Scale (ADAS-Cog)	48
3.3.1.7	Psychogeriatric Assessment Scales (PAS)	48

3.3.1.8	Dementia Rating Scale (DRS)	49
3.3.1.9	Mini-Cog	49
3.3.1.10	Rowland Universal Dementia Assessment Scale (RUDAS)	49
3.3.1.11	The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Neuropsychological Battery (nb) and Other Tests	49
3.4	Brain Imaging in the Diagnosis of Alzheimer's Disease and Other Dementias	51
3.4.1	Imaging Tests in AD Diagnosis: Established Tests	51
3.4.1.1	Computed Tomography (CT)	51
3.4.1.2	Electroencephalography (EEG)	51
3.4.1.3	Magnetic Resonance Imaging (MRI), for the Assessment of Morphological Changes, and the Detection of Stroke	52
3.4.1.4	Positron Emission Tomography (PET)	52
3.4.1.5	FDG-PET	52
3.4.2	Imaging Tests in AD Diagnosis: More Recently Developed Tests	52
3.4.2.1	MRI for Measuring Regional Blood Flow	53
3.4.2.2	Single Photon Emission Computed Tomography (SPECT) Scan	54
3.4.2.3	PiB-PET	54
3.4.3	The Rapidly Evolving Diagnostic Criteria	55
3.4.4	CSF Biomarkers of AD	56
3.4.4.1	A β , Tau, and A β PP-Related Biomarkers	56
3.4.4.2	Other Potential CSF Protein Biomarkers	57
3.4.4.3	Potential Lipid Biomarkers in the CSF	58
3.4.5	Blood Biomarkers of AD	60
3.4.5.1	A β Peptides in Plasma	60
3.4.5.2	Other Potential Blood Biomarkers	62
3.4.5.3	Blood Proteins	62
3.4.6	Blood Lipids	64
3.4.7	Metabolites	65
3.4.8	Blood Platelets	66
3.4.9	Genetic Risk Factors	67
3.4.10	The Eye as a Window to the Brain	68
3.4.11	miRNA Tests	69
3.5	Conclusions	71
	References	72
4	The Link Between Diabetes, Glucose Control, and Alzheimer's Disease and Neurodegenerative Diseases	89
	<i>Giuseppe Verdile, Paul E. Fraser and Ralph N. Martins</i>	
4.1	Introduction	89
4.2	The Impact of Type 2 Diabetes on the Brain	90
4.3	Evidence from Cell Culture, Animal, and Clinical Studies	93
4.3.1	CNS Insulin Signalling and Disruptions in AD	93
4.3.2	The Accumulation of A β Is Associated with Impaired Insulin Signalling	94
4.3.3	Insulin Resistance Promotes the Accumulation of A β	95
4.3.4	Impairments in Insulin Signalling Can Induce Hyperphosphorylation of Tau	96
4.3.5	Type 2 Diabetes and Neuroinflammation	96

4.3.6	Oxidative Stress and Mitochondrial Dysfunction in T2D and AD	97
4.3.7	Targeting Type 2 Diabetes to Slow Down Progression/Prevent Neurodegeneration and Cognitive Decline	99
4.4	Conclusions	103
	References	103
5	Diet and Nutrition, and their Influence on Alzheimer's Disease and other Neurodegenerative Diseases	117
	<i>Stephanie R. Rainey-Smith, Rhona Creegan, Stephanie J. Fuller, Michele L. Callisaya and Velandai Srikanth</i>	
5.1	Introduction	117
5.2	Dietary Patterns	118
5.3	Key Macronutrients	119
5.3.1	Dietary Fatty Acids	119
5.3.2	Cholesterol	120
5.3.3	Polyunsaturated Fatty Acids	121
5.3.4	Dietary Carbohydrates	122
5.4	Key Micronutrients	124
5.4.1	Water Soluble Vitamins	125
5.4.1.1	B Vitamins	125
5.4.2	Fat Soluble Vitamins	128
5.4.2.1	Vitamin A (Retinol, Retinal, and Retinoic Acid)	128
5.4.2.2	Vitamin D	129
5.4.2.3	Vitamin E	130
5.4.3	Dietary Minerals	131
5.4.3.1	Selenium	131
5.4.3.2	Manganese	132
5.4.3.3	Zinc, Iron, Copper, and Calcium	132
5.5	Conclusion	134
	References	135
6	Carbohydrate and Protein Metabolism: Influences on Cognition and Alzheimer's Disease	149
	<i>W.M.A.D. Binosh Fernando, Veer B. Gupta, Vijay Jayasena, Charles S. Brennan and Ralph N. Martins</i>	
6.1	Carbohydrates	149
6.1.1	Carbohydrate Digestion	149
6.1.2	Glucose Ingestion and Use	151
6.1.3	Glucose and Insulin, Insulin Resistance, and Type 2 Diabetes (Short Summary)	151
6.1.4	Relative Intake of Carbohydrate and Its Impacts on Neurodegenerative Disease Risk	152
6.1.5	Ketogenic Diets	154
6.1.6	Glucose and Its Effects on Cognition	154
6.1.7	Possible Mechanisms Related to Memory Enhancement with Glucose	157
6.1.7.1	Glucose and the Hippocampus	158
6.1.7.2	Glucose Availability in Brain Cells	158

6.1.7.3	Glucose and the Central Cholinergic System	159
6.1.7.4	ATP-Regulated Potassium (K-ATP) Channels and Brain Control of Glucose Homeostasis	159
6.1.7.5	Effects of High Fructose Diets	160
6.1.7.6	Sucrose	161
6.2	Proteins	161
6.2.1	Protein Metabolism in General	162
6.2.2	Links Between Specific Amino Acids and Brain Function	163
6.2.2.1	Tryptophan	163
6.2.2.2	Tyrosine	164
6.2.3	Clinical Studies of Protein Supplementation	165
6.2.4	Links Between Loss of Protein Function and Neurodegeneration	167
6.2.5	Clearance Mechanisms Associated with Proteinopathies Involved in Neurodegeneration	168
6.2.6	Role of Protein Crosslinking and Inflammation in Neurodegeneration and AD	170
6.3	Conclusion	171
	References	171
7	Fat and Lipid Metabolism and the Involvement of Apolipoprotein E in Alzheimer's Disease	189
	<i>Eugene Hone, Florence Lim and Ian J. Martins</i>	
7.1	Introduction	189
7.2	Alzheimer's Disease	189
7.3	Cholesterol and Lipid Metabolism	190
7.3.1	Cholesterol Synthesis and Metabolism	190
7.3.2	Oxysterols	191
7.3.2.1	Oxysterols in AD	191
7.3.3	Pathways of Dietary (Exogenous) Lipid Homeostasis	192
7.3.4	Pathways of Endogenous Lipid Homeostasis	193
7.3.5	Peripheral Clearance of Lipoproteins and Reverse Cholesterol Transport	195
7.3.5.1	Lipoproteins in the CNS	197
7.4	Apolipoprotein E Alleles and Isoforms	197
7.4.1	ApoE in the Brain	198
7.4.2	Apolipoprotein E and Alzheimer's Disease	198
7.4.2.1	ApoE Binding to A β	199
7.4.2.2	ApoE in the Cellular Clearance of A β	200
7.4.2.3	ApoE and Antioxidant Properties	201
7.4.2.4	ApoE and Tissue Transglutaminase	201
7.4.2.5	Apolipoprotein J (Clusterin, CLU)	202
7.5	LRP-1 in the Brain and Its Role in A β Clearance	203
7.5.1	LDL, HDL, and AD	203
7.5.2	Statins, Cholesterol, and AD	204
7.6	The Role of Lipid Rafts in Neurodegenerative Diseases	205
7.7	Changes to Glycerophospholipids in Alzheimer's Disease	206
7.7.1	Omega-3 and Omega-6 Fatty Acids	207

7.7.1.1	Omega-3 Fatty Acids, Modern Diets, and Health Implications	208
7.8	Sphingolipids	208
7.8.1	Ceramides	208
7.8.2	Sulfatides	209
7.8.3	Gangliosides	209
7.9	Conclusions	210
	References	210
8	Inflammation in Alzheimer's Disease, and Prevention with Antioxidants and Phenolic Compounds – What Are the Most Promising Candidates?	233
	<i>Matthew J. Sharman, Giuseppe Verdile, Shanmugam Kirubakaran and Gerald Münch</i>	
8.1	Introduction	233
8.2	Inflammation and the Immune Response in AD	233
8.2.1	The Role of Microglia and Astrocytes in Chronic Inflammation in AD	233
8.3	Oxidative Stress	236
8.3.1	Advanced Glycation End Products	237
8.3.2	Involvement of the Complement System in AD	238
8.3.3	Involvement of Cytokines and Chemokines in Inflammation	239
8.3.4	Inflammation – Susceptibility to A β Deposition or Aggregation	240
8.3.5	Inflammation Can Influence A β PP Metabolism and A β Clearance Directly	241
8.4	Current Medications for AD	242
8.4.1	Current Medications – Acetylcholinesterase Inhibitors and Memantine	242
8.5	Disease Modification and Treatment Approaches	243
8.5.1	Non-Steroidal Anti-Inflammatory Drugs (NSAID)	243
8.6	Some Anti-inflammatory Foods, Supplements, and Newly Developed Drugs for the Treatment of AD	244
8.6.1	Cinnamon/Cinnamaldehyde	244
8.6.2	(–)Epigallocatechin-3-Gallate (EGCG) and Other Green Tea Polyphenols	245
8.6.3	Curcumin	247
8.6.4	Other Polyphenolic Antioxidants	248
8.6.5	Omega-3 (n-3) Essential Fatty Acids	249
8.6.6	Lipoic Acid	250
8.7	Conclusion	253
	References	253
9	Cognitive Impairments in Alzheimer's Disease and Other Neurodegenerative Diseases	267
	<i>Hamid R. Sohrabi and Michael Weinborn</i>	
9.1	Introduction	267
9.2	Dementia due to Alzheimer's Disease	268
9.2.1	Subjective Cognitive Decline [4] and Mild Cognitive Impairment (MCI)	268

9.2.2	Memory Impairments in AD	271
9.2.2.1	Episodic Memory	271
9.2.2.2	Semantic Memory	272
9.2.2.3	Prospective Memory (PM)	272
9.2.3	Attention and Executive Dysfunction in AD	273
9.2.4	Language	274
9.2.5	Visuospatial Abilities	276
9.2.6	Dementia with Lewy Bodies and Parkinson's Disease with Dementia	276
9.2.7	Vascular Dementia	277
9.2.8	Frontotemporal Dementia	279
9.3	Conclusions	281
	References	282
10	Animal Models of Alzheimer's Disease	291
	<i>Prashant Bharadwaj</i>	
10.1	Introduction	291
10.2	Transgenic Mouse Models	292
10.3	Knock-in AD Mice Models	296
10.4	Non-Transgenic and Other Mammalian Animal Models	297
10.5	Drug Development and Translational Issues	298
10.6	Correlations Between Animal Models of AD and Human AD	300
10.7	Experimental Design and Reporting	301
10.8	The Future of Animal Models in AD	302
	References	303
11	The Products of Fermentation and Their Effects on Metabolism, Alzheimer's Disease, and Other Neurodegenerative Diseases: Role of Short-Chain Fatty Acids (SCFA)	311
	<i>W.M.A.D Binoshia Fernando, Charles S. Brennan and Ralph N. Martins</i>	
11.1	Introduction	311
11.2	Fermentable Substrates and Short-Chain Fatty Acids	312
11.2.1	Colonic Microflora and Fermentation	313
11.2.1.1	Probiotics and Prebiotics	313
11.2.2	Propionic Acid (PPA)	315
11.2.3	Acetic Acid	315
11.2.4	Butyric Acid	315
11.2.5	Short-Chain Fatty Acids and Free Fatty-Acid Receptor Signalling	316
11.2.6	Short-Chain Fatty Acids and Energy Intake	316
11.2.7	Short-Chain Fatty Acids and Energy Expenditure	319
11.2.8	Regulation of Fatty-Acid Metabolism by SCFA	320
11.2.9	Effect of Short-Chain Fatty Acids on Glucose Regulation	320
11.2.10	Regulation of Cholesterol Metabolism by Short-Chain Fatty Acids	321
11.2.11	Regulation of Inflammation by Short-Chain Fatty Acids	322
11.2.12	Short-Chain Fatty Acids and Neuroprotection	324
11.3	Conclusions	325
	References	326

12	Hormonal Expression Associated with Alzheimer's Disease and Neurodegenerative Diseases	335
	<i>Giuseppe Verdile, Anna M. Barron and Ralph N. Martins</i>	
12.1	The Hypothalamic–Pituitary–Gonadal (HPG) Axis	335
12.1.1	Dysregulation of the HPG Axis During Ageing	336
12.2	Roles for Sex Steroids and Gonadotropins in the Neurodegenerative Process in AD	339
12.2.1	Sex Steroids Modulate A β Accumulation	340
12.2.2	Sex Steroids and Oxidative Stress	342
12.2.3	Sex Steroids and Inflammation	344
12.2.4	Testosterone and Diabetes	346
12.2.5	A Role for Gonadotropins in AD Pathogenesis	347
12.3	Hormone-based Therapies	349
12.3.1	The Oestrogens	349
12.3.2	Testosterone Therapy	350
12.3.3	Selective Oestrogen or Androgen Receptor Modulators (SERM or SARM)	352
12.3.4	Gonadotropin-Lowering Agents	354
12.4	Conclusions	355
	References	355
13	The Link Between Exercise and Mediation of Alzheimer's Disease and Neurodegenerative Diseases	371
	<i>Belinda Brown and Tejal M. Shah</i>	
13.1	Introduction	371
13.2	Physical Activity Promotes Health and Well-being	372
13.3	Neuroplasticity	372
13.4	The Link Between Physical Activity and Cognition Across the Human Lifespan	373
13.4.1	Childhood	373
13.4.2	Adulthood and Midlife	374
13.4.3	Older Adults	375
13.5	Physical Activity Reduces the Risk of Dementia and AD	376
13.6	Mechanisms Underlying the Relationship Between Exercise and Brain Health	376
13.6.1	Evidence from Molecular and Cellular Research	377
13.6.2	Neurotrophins	378
13.6.3	Hormonal Pathways	379
13.6.4	Cardiovascular and Metabolic Mechanisms	380
13.6.5	Evidence from Neuroimaging Studies	380
13.7	The Effect of Genetics on the Relationship Between Exercise and Brain Health	381
13.8	Future Directions	382
	References	382

14	Current and Prospective Treatments for Alzheimer's Disease (and Other Neurodegenerative Diseases) 391
	<i>Steve Pedrini, Mike Morici and Ralph N. Martins</i>
14.1	Introduction 391
14.2	Current and Potential Medical Treatments 391
14.2.1	Treatments That Influence Neurotransmission 391
14.2.1.1	Cholinergic System 391
14.2.1.2	Other Neurotransmitters 396
14.2.2	Cholesterol-Lowering Medications 399
14.2.3	Immunotherapy 400
14.2.3.1	Active Immunotherapy (A β) 401
14.2.3.2	Active Immunotherapy (tau) 402
14.2.3.3	Passive Immunotherapy (A β) 402
14.2.3.4	Passive Immunotherapy (tau) 404
14.2.4	Targeting the A β -Producing Pathway 405
14.2.4.1	α -Secretase 406
14.2.4.2	β -Secretase 406
14.2.4.3	γ -Secretase 407
14.2.5	Other Compounds Affecting A β 408
14.2.6	Other Compounds Affecting Tau 410
14.2.7	Inflammatory Targets 411
14.3	Conclusions 412
	References 412
15	The Role of Genetics in Alzheimer's Disease and Parkinson's Disease 443
	<i>Tenielle Porter, Aleksandra K. Gozt, Francis L. Mastaglia and Simon M. Laws</i>
15.1	Introduction 443
15.2	Genetics of Alzheimer's Disease 444
15.3	Autosomal Dominant AD (ADAD) 445
15.3.1	Understanding the Importance of APP and the Presenilins in AD 445
15.4	Amyloid Precursor Protein (APP) 447
15.5	Presenilin 1 (PSEN1) 447
15.6	Presenilin 2 (PSEN2) 448
15.7	Genetic Contributions to Sporadic Late-Onset AD (LOAD) 449
15.8	Cholesterol Metabolism 449
15.8.1	Apolipoprotein E (APOE) 449
15.8.2	Clusterin (CLU) 452
15.8.3	ATP-Binding Cassette Transporter A7 (ABCA7) 453
15.9	Immune Response 454
15.9.1	Complement Receptor 1 (CR1) 454
15.9.2	CD33 (Myeloid Cell Surface Antigen CD33; Sialic Acid-Binding Immunoglobulin-Like Lectin 3) 455
15.9.3	Membrane Spanning 4 Domains, Subfamily A (MS4A) 456
15.9.4	Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) 456

15.9.5	Further Genetic Associations Implicating the Immune Response	457
15.10	Endocytosis	458
15.10.1	Bridging Integrator 1 (<i>BINI</i>)	459
15.10.2	Phosphatidylinositol Binding Clathrin Assembly Lymphoid Myeloid Protein (<i>PICALM</i>)	460
15.10.3	CD2-Associated Protein (<i>CD2AP</i>)	461
15.10.4	Further Genetic Associations Implicating Endocytosis	462
15.10.5	Variants in <i>APP</i> and Genes for APP-Metabolising Proteins	463
15.10.6	Further Mechanisms Implicated Through Genetic Associations	464
15.11	Genetics of Parkinson's Disease	465
15.12	Monogenic forms of PD	466
15.12.1	Autosomal Dominant Forms	466
15.12.1.1	PARK 1 (<i>SNCA</i>)	466
15.12.1.2	PARK 8 (<i>LRRK2</i>)	467
15.12.1.3	PARK 11 (<i>GIGYF2</i>)	468
15.12.1.4	PARK 17 (<i>VPS35</i>)	468
15.12.1.5	PARK 18 (<i>EIF4G1</i>)	468
15.12.2	Autosomal Recessive Forms	469
15.12.2.1	PARK 2 (<i>PRKN</i>)	469
15.12.2.2	PARK 6 (<i>PINK 1</i>)	469
15.12.2.3	PARK 7 (<i>DJ-1</i>)	470
15.12.2.4	PARK 9 (<i>ATP13A2</i>)	470
15.12.2.5	PARK 14 (<i>PLA2G6</i>)	470
15.12.2.6	PARK 15 (<i>FBXO7</i>)	471
15.12.3	Genetic Contributions to Late-Onset Sporadic PD (LOPD)	471
15.12.4	Common Variants in PD Genes	471
15.12.5	Glucocerebrosidase (<i>GBA</i>)	472
15.12.6	Immune-Inflammatory Genes	472
15.12.7	Mitochondrial DNA Variants	473
15.13	Conclusion	473
	References	474

Final Thoughts Regarding Alzheimer's Disease, Diet, and Health 499

Charles S. Brennan, Margaret A. Brennan, W.M.A.D. Binosh Fernando, Stephanie J. Fuller and Ralph N. Martins

List of Abbreviations 503**Index** 511